NCT03856411View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

PHASE3CompletedINTERVENTIONAL

Enrollment

465

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

January 9, 2023

Conditions

Treatment-naive Advanced Non-small Cell Lung Cancer

Interventions

DRUG

TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy

TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.

Trial Locations (1)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT03856411 - A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC | Biotech Hunter | Biotech Hunter